Global Oxazolidinones Market Research Report - Segmented by Application (Skin and Soft Tissue Infections, Pneumonia, Others); By Distribution Channels (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies); and Region - Size, Share, Growth Analysis | Forecast (2024 – 2030)
Published: 2024 - January
Report Code: IM-15297
Format:
Region: Global
Chapter 1. Oxazolidinones Market – Scope & Methodology
1.1. Market Segmentation
1.2. Assumptions
1.3. Research Methodology
1.4. Primary Sources
1.5. Secondary Sources
Chapter 2. Oxazolidinones Market – Executive Summary
2.1. Market Size & Forecast – (2023 – 2030) ($M/$Bn)
2.2. Key Trends & Insights
2.3. COVID-19 Impact Analysis
2.3.1. Impact during 2023 - 2030
2.3.2. Impact on Supply – Demand
Chapter 3. Oxazolidinones Market – Competition Scenario
3.1. Market Share Analysis
3.2. Product Benchmarking
3.3. Competitive Strategy & Development Scenario
3.4. Competitive Pricing Analysis
3.5. Supplier - Distributor Analysis
Chapter 4. Oxazolidinones Market - Entry Scenario
4.1. Case Studies – Start-up/Thriving Companies
4.2. Regulatory Scenario - By Region
4.3 Customer Analysis
4.4. Porter's Five Force Model
4.4.1. Bargaining Power of Suppliers
4.4.2. Bargaining Powers of Customers
4.4.3. Threat of New Entrants
4.4.4. Rivalry among Existing Players
4.4.5. Threat of Substitutes
Chapter 5. Oxazolidinones Market - Landscape
5.1. Value Chain Analysis – Key Stakeholders Impact Analysis
5.2. Market Drivers
5.3. Market Restraints/Challenges
5.4. Market Opportunities
Chapter 6. Oxazolidinones Market - By Application
6.1 Skin and Soft tissue infections
6.2 Pneumonia
6.3 Others
Chapter 7. Oxazolidinones Market - By Distribution Channels
7.1 Hospital pharmacies
7.2 Retail pharmacies
7.3 Online pharmacies
Chapter 8. Oxazolidinones Market - By Region
8.1 North America
8.2 Europe
8.3 Asia-Pacific
8.4 Rest of the World
Chapter 9. Oxazolidinones Market - Key Players
9.1 Pfizer Inc
9.2 Merck & Co., Inc
9.3 Entasis Therapeutics Holdings Inc
9.4 Venatorx Pharmaceuticals, Inc
9.5 Wockhardt Ltd
9.6 Tetraphase Pharmaceuticals, Inc
9.7 Paratek Pharmaceuticals, Inc
9.8 Sequoia Sciences, Inc
9.9 Trius Therapeutics, Inc
Download Sample
Choose License Type
2850
5250
4500
1800
Frequently Asked Questions
The class of synthetic antibacterial drugs known as oxazolidinones has a brand-new chemical structure. Their primary bacteriostatic antibacterial action involves inhibiting protein synthesis. The use of oxazolidinones is reserved for severe bacterial infections.
The Global Oxazolidinones Market was estimated to be worth USD 5.21 billion in 2022 and is projected to reach a value of USD 6.91 billion by 2030, growing at a CAGR of 3.6% during the forecast period 2023-2030.
The increasing need for oxazolidinones in pharmaceuticals to treat TB and gram-positive bacterial infections that are multidrug-resistant and the market is seeing an increase in low-cost raw materials for oxazolidinone production.
The market for oxazolidinones may be hampered by the negative effects that some of them, particularly linezolid can have.
Pfizer Inc, Merck & Co., Inc, Entasis Therapeutics Holdings Inc, Venatorx Pharmaceuticals, Inc, Wockhardt Ltd, Tetraphase Pharmaceuticals, Inc, Paratek Pharmaceuticals, Inc, Sequoia Sciences, Inc, Trius Therapeutics, Inc are some key players.
